1. Lloyd MR, Wander SA, Hamilton E, et al. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol. 2022;14:1–25.
2. Menarini Group. Stemline Therapeutics, a subsidiary of Menarini Group, receives U.S. FDA approval for ORSERDU™ (elacestrant) as the first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer [media release]. 30 Jan 2023. https://www.menarini.com/.
3. Stemline Therapeutics Inc. ORSERDU™ (elacestrant) tablets, for oral use: US prescribing information. 2023. https://www.fda.gov/. Accessed 31 Jan 2023.
4. US FDA. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer [media release]. 27 Jan 2023. https://www.fda.gov/.
5. Menarini Group. Menarini Group's elacestrant Marketing Authorization Application accepted for review by the European Medicines Agency (EMA) for the treatment of ER+/HER2- advanced or metastatic breast cancer [media release]. 19 Aug 2022. http://www.menarini.com.